Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT04797286
PHASE2

Sildenafil for Early Pulmonary Vascular Disease in Scleroderma

Sponsor: Johns Hopkins University

View on ClinicalTrials.gov

Summary

This is a Phase II randomized, double-blind, placebo-controlled trial of sildenafil in men and women with Scleroderma with mildly elevated pulmonary pressures (SSc-MEP) to determine whether sildenafil may be an effective treatment for SSc-MEP.

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

30

Start Date

2021-09-20

Completion Date

2026-09-01

Last Updated

2025-10-15

Healthy Volunteers

No

Interventions

DRUG

Sildenafil

Sildenafil 20 mg three times a day. This is the approved dose for the treatment of pulmonary arterial hypertension. It is being studied in this trial with a population who has mildly elevated pulmonary pressures.

OTHER

Placebo

Oral pill placebo.

Locations (2)

Louisiana State University

New Orleans, Louisiana, United States

Johns Hopkins

Baltimore, Maryland, United States